Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications
- 9 June 2010
- journal article
- Published by Wiley in Haemophilia
- Vol. 16 (s6), 13-17
- https://doi.org/10.1111/j.1365-2516.2010.02301.x
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Less severe bleeding in hemophilia B than in hemophilia AJournal of Thrombosis and Haemostasis, 2008
- Validation of a composite score for clinical severity of hemophiliaJournal of Thrombosis and Haemostasis, 2008
- Assessment of Treatment Practice Patterns for Severe Hemophilia A: A Global Nurse PerspectiveActa Haematologica, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIIIHaemophilia, 2006
- Consensus recommendations for use of central venous access devices in haemophiliaHaemophilia, 2004
- What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?Haemophilia, 2001
- Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia AHaemophilia, 1997
- A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacsJournal of Internal Medicine, 1994
- Pharmacokinetic dosing in prophylactic treatment of hemophilia AEuropean Journal of Haematology, 1993